BioLineRx
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, BioLineRx sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,751 sponsors by registered trial count).
BioLineRx: 8 sponsored US clinical trials, none currently recruiting.
BioLineRx sponsors 8 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 6 completed. 1 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Multiple Myeloma, with 1 trials.
Upper-quartile sponsor footprint
BioLineRx sits in the upper quartile of the sponsor corpus (#1,604 of 15,751 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
8 total, page 1 of 1
A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)
NCT03246529
Study to Investigate the Effect of BL-8040 (Motixafortide) on the QTc Interval in Healthy Subjects
NCT05293171
Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance Treatment in Subjects With Acute Myeloid Leukemia (AML)
NCT03154827
Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients
NCT02826486
Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome
NCT02462252
Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients
NCT01838395
A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II Study
NCT00567710
Extension Study To Evaluate The Long-Term Safety, Tolerability, And Efficacy Of Low And High Doses Of Bl-1020
NCT00722176
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 5 |
| Phase 3 | 1 |
Therapeutic Areas
How the BioLineRx early-phase archive is shaped
8 indexed studies, none listed as recruiting (0% open); 6 completed (75%).
Phase mix: 1 late (III/IV) vs 7 early (I/II) (early-phase heavy).
Top condition: Multiple Myeloma (1 trial), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.